ni Mary Gutierrez Almirañez | April 14, 2021
Inirekomenda ng U.S Food and Drug Administration (FDA) at Centers for Disease Control and Prevention (CDC) na ihinto muna ang pagbabakuna kontra COVID-19 gamit ang Johnson & Johnson ng Janssen Pharmaceuticals dahil sa iniulat na blood clot sa 6 na nabakunahan nito.
Ayon sa tweet ng U.S FDA kagabi, “Today FDA and @CDCgov issued a statement regarding the Johnson & Johnson #COVID19 vaccine. We are recommending a pause in the use of this vaccine out of an abundance of caution.”
Dagdag pa nila, "Until that process is complete, we are recommending this pause. This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot."
Base sa huling tala, mahigit 6.8 milyong indibidwal na ang nabakunahan ng Johnson & Johnson COVID-19 vaccines, kung saan ang anim na nakaranas ng severe blood clot ay mga babaeng nasa edad 18 hanggang 48-anyos. Naranasan nila ang pamumuo ng dugo makalipas ang 6 hanggang 13 araw matapos silang mabakunahan ng unang dose.
Batay din sa lumabas na statement ng mga eksperto, “In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia)… Usually, an anticoagulant drug called herapin is used to treat blood clots. In these setting, administration of herapin may be dangerous, and alternative treatments need to be given.”
Ngayong Miyerkules ay makikipag-meeting ang U.S FDA sa Advisory Committee on Immunization Practices (ACIP) upang mapag-usapan ang tungkol sa nadiskubreng adverse event sa nasabing bakuna.
Matatandaang nauna nang ipinahinto ang pagbabakuna ng AstraZeneca dahil sa blood clot na kumitil sa buhay ng 29 indibidwal matapos mabakunahan nito.
Samantala, inaasahan namang mapipirmahan ngayong linggo ang supply agreement at emergency use authorization (EUA) ng Johnson & Johnson upang mai-deliver sa ‘Pinas ang 6 milyong doses nito.